Form 4: United Therapeutics COO Executes Pre-Planned Stock Sales

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares through a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), reported transactions on December 1, 2025, involving the exercise of stock options and subsequent sale of common stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan, which was established on June 3, 2025.
• Benkowitz exercised 14,625 stock options at an exercise price of $117.76 per share.
• He also exercised an additional 7,875 stock options at an exercise price of $146.03 per share.
• Following the exercise, 14,625 shares of common stock were sold at weighted average prices ranging from $477.939 to $483.4167.
• An additional 7,875 shares of common stock were sold at weighted average prices ranging from $477.9389 to $483.4167.
• All reported transactions involved shares held indirectly by trusts, with the reporting person having shared or sole investment and voting power.
• After these transactions, the beneficial ownership of common stock from the exercised options in both trusts is 0.00 shares.
• Remaining derivative securities beneficially owned include 170,250 stock options (by Trust 2) and 21,940 stock options (by Trust 10).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the execution under a pre-planned 10b5-1 trading plan makes it a routine event for personal financial management rather than a signal of company-specific concerns.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned sales for diversification or liquidity rather than reactive selling based on new information.
• The significant difference between the option exercise prices ($117.76 and $146.03) and the sale prices (ranging from $477.30 to $483.43) indicates substantial gains for the insider from these long-held options.

Negatives

• The sale of common stock by a high-ranking insider reduces their direct equity stake in the company, which some investors might interpret as a lack of confidence, although mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for a publicly traded company and does not inherently reflect broader industry trends or competitive positioning. It primarily relates to an individual executive's personal financial planning.

Related Party Transactions

• The transactions involved shares held indirectly by trusts, where the reporting person is a beneficiary and/or co-trustee with shared investment and voting power, or has sole investment and voting power for family member beneficiaries.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived as a slight reduction in insider alignment, though the pre-planned nature mitigates negative interpretations.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Executive Compensation, Share Sale, Beneficial Ownership